Spontaneous regression of cutaneous head and neck melanoma: Implications for the immunologic control of neoplasia

Head and Neck

Volumn 30, Issue 2, 2008, Pages 267-272

  Dunn, Gavin P ^a   Lewis Jr , James S ^b   Sunwoo, John B ^b   Uppaluri, Ravindra ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunoediting; Immunotherapy; Melanoma; TIL; Tumor

Indexed keywords

ADULT; ARTICLE; CANCER CONTROL; CANCER REGRESSION; CASE REPORT; FAMILY HISTORY; FEMALE; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; LYMPHOSCINTIGRAPHY; MELANOMA; METASTASIS; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; SKIN CANCER; TUMOR BIOPSY;

ADULT; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM REGRESSION, SPONTANEOUS; S100 PROTEINS; SKIN NEOPLASMS;

EID: 39149137539     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20701     Document Type: Article

References (32)

1. Barnhill RL. Pathology of malignant melanoma. New York: Springer; 2004.
2. Katz KA, Jonasch E, Hodi FS, et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 2005;15:77-82.
3. Nathanson. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. Natl Cancer Inst Monogr 1976;44:67-76.
4. Papac RJ. Spontaneous regression of cancer: possible mechanisms. In Vivo 1998;12:571-578.
5. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
6. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
7. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-360.
8. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-148.
9. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 1971;28:89-98.
10. Penn I. Malignant tumors in organ transplant recipients. New York: Springer-Verlag; 1970. 51 p.
11. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-365.
12. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998;187:1163-1167.
13. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999;10:281-287.
14. Clark WH Jr, Elder DE, Guerry Dt, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-1904.
15. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-1310.
16. Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996;74:43-47.
17. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213.
18. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-18543.
19. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-3494.
20. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-2666.
21. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61:5132-5136.
22. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61:3932-3936.
23. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small cell lung cancer. J Clin Oncol 2005;23:8959-8967.
24. Ohno S, Inagawa H, Dhar DK, et al. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 2003;23:5015-5022.
25. Everson TC, Cole WH. Spontaneous regression of cancer. Philadelphia: W. B. Saunders; 1966.
26. McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology 1983;7:673-680.
27. Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992;20:315-322.
28. Barnetson RS, Halliday GM. Regression in skin tumours: a common phenomenon. Australas J Dermatol 1997;38(Suppl 1):S63-S65.
29. Kang S, Barnhill RL, Mihm MC Jr, Sober AJ. Histologic regression in malignant melanoma: an interobserver concordance study. J Cutan Pathol 1993;20:126-129.
30. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-350.
31. Bingle L, Brown NJ, Lewis CE. The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol 2002;196:254-265.
32. Printz C. Spontaneous regression of melanoma may offer insight into cancer immunology. J Natl Cancer Inst 2001;93:1047-1048.